• In late April 2026, partner GSK announced that the FDA accepted for Priority Review the New Drug Application for bepirovirsen, an antisense therapy for chronic hepatitis B licensed from Ionis, while Ionis also raised its 2026 total revenue guidance to US$875 million–US$900 million and reported first-quarter revenue of US$246.09 million with a reduced net loss of US$92.53 million.
• Together, the expedited regulatory path for bepirovirsen and Ionis’ higher full-year revenue outlook highlight how partnered late-stage assets and improving top-line performance are becoming increasingly important to the company’s profile.
• We’ll now examine how the FDA’s Priority Review for bepirovirsen could influence Ionis’ investment narrative and future growth expectations.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 19 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

Ionis Pharmaceuticals Investment Narrative Recap

To own Ionis, you need to be comfortable with a story built on high-risk RNA medicines where a few late-stage assets drive much of the value. In that context, GSK’s Priority Review for bepirovirsen and Ionis’ higher 2026 revenue guidance may sharpen attention on the near term approval path for Olezarsen and Donidalorsen, while the main risk remains how pricing, payer pushback and reliance on a small set of launches could affect revenue quality.

The April guidance raise to US$875 million to US$900 million in 2026 revenue sits alongside the bepirovirsen Priority Review and underscores how partnered programs can reinforce Ionis’ own launch pipeline. This updated outlook ties directly into the broader catalyst stack around multiple 2026 FDA decisions, but it does not remove the longer term concerns about pricing pressure as Ionis moves from rare diseases into larger populations.

Yet investors should be aware that while consensus focuses on growth and new launches, the real pressure point may be how much pricing power Ionis can actually sustain over time...

Ionis Pharmaceuticals’ narrative projects $1.9 billion revenue and $82.2 million earnings by 2029.

Uncover how Ionis Pharmaceuticals' forecasts yield a $96.73 fair value, a 29% upside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts were only baking in about 3 percent annual revenue growth and ongoing losses, so compared with today’s Priority Review momentum they are painting a far more cautious picture that you may want to weigh against your own view.

Explore 3 other fair value estimates on Ionis Pharmaceuticals - why the stock might be worth 17% less than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Ionis Pharmaceuticals research is our analysis highlighting 2 key rewards that could impact your investment decision.
• Our free Ionis Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Ionis Pharmaceuticals' overall financial health at a glance.

Want Some Alternatives?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Uncover the next big thing with 22 elite penny stocks that balance risk and reward.
• Capitalize on the AI infrastructure supercycle with our selection of the 38 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.